Background. Nitric oxide (NO) has been identified as endothelium-derived relaxing factor (EDRF), which, in addition to its relaxant effects on vascular smooth muscle cells, is also a potent inhibitor of platelet aggregation. An inhibitory role on platelet adhesion has been suggested from experiments with washed platelets under static conditions. We have determined whether endothelium-derived and exogenous NO also regulates platelet adhesion in whole blood under flow conditions. Methods and Results. The effect of endothelium-derived NO was studied by the addition of specific inhibitors of NO production, L-N-monomethyl arginine (L-NMMA) and N-iminoethyl-L-ornithine (L-NIO), to a perfusion system in which both endothelial cells and their matrices were present. A concentration-dependent increase in platelet adhesion to the matrix was found with a maximum inhibition at a concentration of 2 mM L-NMMA and 0.1 mM L-NIO. The effect was dependent on the presence of endothelial cells, because no increase in platelet adhesion was observed in their absence. The effect of exogenous NO was tested in a specially devised perfusion system in which the NO was introduced at the site of adhesion by means of a porous membrane on which an extracellular matrix of endothelial cells was present. Inhibition of platelet adhesion by NO was found at all shear rates tested and after all perfusion periods.
T he discovery of the obligatory role of endothelial cells for the action of various vascular relaxation agents focused attention on endotheliumderived factors in the control of vascular tone.'2 In addition to prostacyclin, a specific endothelium-derived relaxation factor (EDRF) was discovered that was recently identified as nitric oxide (NO).3 The elucidation of its synthesis from L-arginine4-6 and the development of specific inhibitors has allowed study of the role of NO in other biological processes. In addition to its relaxant effects on vascular smooth muscle cells, EDRF is a potent inhibitor of platelet function in vitro. 7 The inhibitory effect of EDRF on platelet aggregation has been shown to be accounted for by NO.8 9 The inhibition was associated with an elevation of the intracellular cyclic GMP (cGMP) levels in the platelets.10 EDRF has also been reported to inhibit platelet adhesion, and it has been suggested that the release of NO contributes to the nonadhesive properties of vascular endotheli-um.1-13 All the evidence for the inhibitory effect of NO on platelet function has been derived under static conditions with platelet-rich plasma or with washed platelets. The interaction of platelets with the vessel wall, however, is strongly dependent on the presence of red blood cells and the shear rate of the blood.14'5 Also, the synthesis of EDRF by endothelial cells has been demonstrated to be dependent on shear rate.'6'7 NO is very unstable and extremely sensitive to inactivation by hemoglobin.'8"9 As a consequence, it has been suggested that NO is transferred directly from the endothelial cells to the vascular smooth muscle cells or to platelets when they come in close contact with the endothelium. 7 We now present studies on the inhibition of platelet adhesion by NO under flow conditions. The extremely short life of NO forced us to devise a special perfusion system in which authentic NO is introduced at the site of platelet adhesion by use of a porous membrane on which an extracellular matrix of endothelial cells is present. Diffusion of NO through the adhesive surface present on the porous membrane limited the direct interaction of NO with the circulating plasma as much as possible. We also studied the role of endotheliumderived NO on platelet adhesion under flow using the specific inhibitors of NO production L-N-monomethyl arginine (L-NMMA) and N-iminoethyl-L-ornithine (L-NIO).20-23 Under these conditions, we were able to show that NO inhibits platelet adhesion in whole blood under flow conditions.
Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords according to the method originally described by Jaffe et a124 with some minor modifications.25 Culture medium consisted of RPMI-1640 (Gibco, Paisley, UK) supplemented with 20% pooled human serum, penicillin (100 U/mI), and streptomycin (100 ,ug/ml).
Porcine aortic endothelial cells (PAECs) were isolated from fresh porcine thoracic aortae obtained from an abattoir. After the lumen had been rinsed with phosphate-buffered saline (PBS; 1:10 chamber is based on the double rectangular perfusion chamber as has been described by Sakariassen et al. 29 The main modification concerns one of the two plugs, both of which contain a coverslip in the original system. For present purposes, a central cavity 14 mm long, 12 mm wide, and 5 mm deep has been constructed in the first plug. This cavity is connected to the top of the plug by two eccentrically placed channels with an internal diameter of 1.0 mm. A polycarbonate micropore membrane containing the ECM is placed over the bottom side of the plug, thereby covering the open side of the central cavity. The plug is placed into the perfusion chamber with the longitudinal axis of the central cavity perpendicular to the direction of blood flow and with the ECM-containing side directed toward the blood stream. The filter thereby serves as part of the roof of the flow chamber that is formed when part A, containing the plugs, and part B, containing the inlet and outlet, are joined together by screws (see Figure 1) .
In part B of the perfusion chamber, a hole with a diameter of 1.2 mm is constructed in the middle of the flow channel, just opposite the center of the first upstream perfusion plug. This plug contains, in addition to the two eccentrically placed channels, a third channel in its center. This central channel also connects the central cavity to the top side of the plug. The central channel in the perfusion plug and the channel in part B of the perfusion chamber are connected to Silastic tubing with an internal diameter of 0.6 mm; they are kept perpendicular to the horizontal plane and serve to detect the fluid pressure at either side of the membrane. The fluid pressure, represented by the height of the fluid column in the tubes, was adjusted by regulating the outflow of the central cavity in the plug to prevent a pressure gradient across the membrane at specific shear rates of the blood.
With this perfusion chamber, the ECM on the membrane is exposed to flowing blood while on the other side of the filter, saline with or without added NO was circulated through the central cavity of the plug. The NO (>99.89% pure, British Oxygen Corp.) was prepared as 3.0% (vol/vol) solutions in helium-deoxygenated saline as described3 and circulated by means of a roller pump at a constant flow rate of 2.5 ml/min.
Platelet adhesion to the ECM present on the filter was determined at various wall shear rates and after perfusion times ranging from 5 to 15 minutes.
Perfusates. Perfusions were carried out as has been described elsewhere. 29 In short: Blood from healthy donors who had not taken any platelet-inhibiting drugs for at least 7 days was collected into 3.1% (wt/vol) sodium citrate (1 ml of citrate to 9 ml of blood). The blood was kept at room temperature. Before the start of the perfusions, the perfusion chamber was rinsed with 25 ml prewarmed (37°C) HEPES The results were expressed as mean+SEM for (n) separate experiments. Student's t test was used to determine the significance of differences between means, and a value of p<0.05 was taken as statistically significant.
Results
Effects of Endogenous Nitric Oxide
PAECs. In a confluent endothelial cell monolayer, a narrow band of endothelial cells was removed by cellulose acetate stripping. When these monolayers were perfused for 5 minutes at a shear rate of 100 sec '(shear stress, 2.5 dynes/cm2), platelet adhesion to exposed matrix without the addition of L-NMMA was 8.5 + 1.8% (n=8) (Figure 2 ). Addition of L-NMMA to the perfusate resulted in a concentration-dependent increase in platelet adhesion up to a concentration of 2 mM. The maximum platelet coverage was 17.0+2.3% (p<0.02). At higher concentrations, the platelet adhesion gradually decreased to 11.2+2.0% at 3 mM. No platelets were found adhering to the intact endothelial cell layer, not only in the absence of inhibitors but also when both prostacyclin synthesis and NO production of the cells were maximally inhibited (not shown).
HUVECs. Platelet adhesion to the matrix of HUVECs in the presence of endothelial cells is shown in Figure 3 Light microscopic evaluation revealed that the inhibiting effect of NO was caused by a decreased number of platelets adhering to the matrix and not by decreased spreading of the platelets (Figure 6 ).
Shear rate dependence. Platelet adhesion to the ECM present on the filter was determined in the presence or absence of NO after a perfusion time of 5 minutes at shear rates from 300 to 1,800 sec`1 (shear stresses, 7.5-45 dynes/cm2). The results are presented in Figure   7 . In the absence of NO (upper curve), 45.5-+5.3% of the ECM was covered with platelets at the highest wall shear rate tested (1,800 sec-'). The presence of NO (lower curve) reduced platelet adhesion to 25.1±2.6% (45% inhibition) (p<0.02). When expressed as percentage reduction of platelet coverage, the inhibiting effect of NO was stronger at the lower shear rates. The presence of NO reduced platelet adhesion from 18.3±0.9% to 8.4±0.8% (pc0.05) at a shear rate of 300 sec`. To investigate the role of locally produced NO in platelet adhesion, we have studied the effect of endothelium-derived NO on platelet adhesion to the matrix of cultured porcine and human endothelial cells. Cultured PAECs have been reported to release sufficient amounts of NO to account for the antiplatelet activities attributed to EDRF.32 The effect of endothelium-derived NO was tested at a shear rate of 100 sec`because at higher shear rates the endothelial cells detach, which may influence the results.
In the presence of both endothelial cells and extracellular matrix, the addition of the specific inhibitors of NO synthesis L-NMMA or L-NIO resulted in a concentration-dependent increase in platelet adhesion to the matrix. With regard to the antiaggregatory effect of NO, a synergistic interaction between NO and prostacyclin has been demonstrated.9 Pretreatment of the endothelial cells with aspirin, however, did not result in a further increase in platelet adhesion. The antiaggregating and disaggregating activity of NO and prostacyclin are mediated by cGMP and cyclic AMP, respectively.10.37 Prostacyclin is only a weak inhibitor of platelet adhesion, and it has been suggested that it is the cGMP system in platelets that selectively controls those membrane properties associated with platelet adhesion.38 However, we could not exclude the possibility of a synergistic effect of prostacyclin and NO at suboptimal concentrations of both endothelial cell products.
To further elucidate the role of NO on platelet adhesion under flow conditions, the effect of exogenous NO on platelet adhesion to the matrix of HUVECs was studied. In the experiments in which exogenous NO was added to the flowing blood just before the start of the perfusion, no influence of NO on platelet adhesion to the matrix of cultured endothelial cells was found. This is likely to be a result of immediate inactivation of NO in whole blood. Therefore, a special perfusion setup was used in which exogenous NO was introduced at the site of platelet adhesion, thereby reducing the direct interaction of NO with the circulating plasma and red blood cells as much as possible. In this way, addition of NO resulted in a significant reduction of platelet adhesion to the ECM. The effect was present at all the conditions tested and was most pronounced after short perfusion times. Platelet adhesion to ECM was decreased to about 50% when NO was diffused through the porous membrane to the matrix. In the experiments in which endogenous NO production by endothelial cells was inhibited, the maximal increase in platelet adhesion to the matrix downstream from the endothelial cells was about 200% of the control value. Therefore, the maximal inhibitory effects of endogenous and exogenous NO on platelet adhesion were comparable. These results indicate that under flow conditions, NO produced by endothelial cells can reduce platelet adhesion to exposed extracellular matrix in their vicinity by at least 50%.
When NO production by endothelial cells was inhibited, no platelets adhered to the endothelial cells. Even when the production of both NO and prostacyclin was inhibited, no platelet adhesion to endothelial cells was observed. These results indicate that NO production and prostacyclin synthesis are not the major cause for the nonthrombogenicity of an intact endothelial cell surface.
The present experiments demonstrate the inhibiting effect of exogenous NO on platelet adhesion to the ECM under flow conditions and suggest that locally produced NO may reduce platelet deposition on endothelial cell injuries in close proximity to endothelial cells. The effect of NO on platelets has been demonstrated to be associated with an elevation of platelet cGMP.'0 Additional support for the inhibitory role of NO in platelet adhesion could have been obtained by the demonstration of a concomitant increase in platelet cGMP. Further experiments will be carried out to measure an increase in cGMP levels in the platelet present in the perfusate.
In conclusion, we have shown that NO inhibits platelet adhesion to the matrix of cultured endothelial cells under flow conditions. We also found that endotheliumderived NO reduces platelet adhesion immediately downstream of its site of release. This implies that under flow conditions and in the presence of red blood cells, the intravascular release of NO may have a definite inhibitory effect on platelets passing in close proximity to the endothelium and thereby contributes to the regulatory role of endothelial cells in platelet-vessel wall interaction.
